Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

Detalles Bibliográficos
Autores principales: Bai, Wei, Yang, Fan, Xu, Huji, Wei, Wei, Li, Hongbin, Zhang, Liyun, Zhao, Yi, Shi, Xiaofei, Zhang, Yan, Zeng, Xiaofeng, Leng, Xiaomei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388526/
https://www.ncbi.nlm.nih.gov/pubmed/37525264
http://dx.doi.org/10.1186/s13063-023-07546-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388526/
https://www.ncbi.nlm.nih.gov/pubmed/37525264
http://dx.doi.org/10.1186/s13063-023-07546-z

Ejemplares similares